COSENTYX is the first FDA-approved biologic of its kind, an IL-17A blocker. 

​

COSENTYX® (secukinumab) is a prescription medicine used to treat:

• people 6 years of age and older with moderate to severe plaque psoriasis (PsO) that involves large areas or many areas of the body, and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light alone or with systemic therapy)

• people 2 years of age and older with active psoriatic arthritis (PsA)

• adults with active ankylosing spondylitis (AS)

• adults with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation 

• people 4 years of age and older with active enthesitis-related arthritis (ERA)

• adults with moderate to severe hidradenitis suppurativa (HS)